Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me (Q30376023)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me |
scientific article |
Statements
1 reference
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me (English)
1 reference
Luca Gianni
1 reference
Anna Lladó
1 reference
Giulia Bianchi
1 reference
Javier Cortes
1 reference
Pirkko-Liisa Kellokumpu-Lehtinen
1 reference
David A Cameron
1 reference
David Miles
1 reference
Stefania Salvagni
1 reference
Andrew Wardley
1 reference
Jean-Charles Goeminne
1 reference
Veronica Hersberger
1 reference
José Baselga
1 reference
1 February 2010
1 reference
1 reference
1131-1137
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference